US FDA declines to approve Summit lung cancer drug after trial misses key survival goal

Summary
(MedPage Today) -- The FDA declined to approve a closely watched drug developed in China for an indication in non-small cell lung cancer (NSCLC), drugmaker Summit Therapeutics announced, though the investigational bispecific antibody could soon... Covered by 5 outlets: 1 lean left, 3 are centre, 1 lean right.
Automated summary picked from the outlets' own descriptions.
Who is covering this
-
China Approved This Lung Cancer Drug. The FDA Is Making Americans Wait.
Red background with packaging for a Chinese lung cancer drug
-
FDA Rejects China's Cancer Drug as 'Blow to Beijing' Framing Unleashes Fury Over American Lung Cancer Patients
The FDA rejected ivonescimab after its trial failed to show a statistically significant overall-survival benefit, despite delaying lung cancer progression in previously treated patients.
-
US FDA approves Roche's oral treatment for advanced breast cancer - Reuters
US FDA approves Roche's oral treatment for advanced breast cancer Reuters
-
FDA Declines Approval of China-Developed Lung Cancer Drug After Survival Goal Missed
The U.S. Food and Drug Administration in White Oak, Md., on June 5, 2023. (Madalina Vasiliu/The Epoch Times)
Low reliability sourceElevated risk -
FDA Rejects Promising Cancer Drug Developed in China
(MedPage Today) -- The FDA declined to approve a closely watched drug developed in China for an indication in non-small cell lung cancer (NSCLC), drugmaker Summit Therapeutics announced, though the investigational bispecific antibody could soon...
-
FDA declined to approve Summit Therapeutics' lung cancer drug
The agency said ivonescimab lacks a statistically significant overall survival benefit; Summit said it will continue development
-
US FDA declines to approve Summit lung cancer drug after trial misses key survival goal - Reuters
US FDA declines to approve Summit lung cancer drug after trial misses key survival goal Reuters








Comments
Comments need JavaScript.